The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. Since the last review it its composite score rose.
Alamar Biosciences, Inc.
ALMR · Nasdaq · USD · Market cap $1.9B · 222 employees
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases.
PASS · Titan Ethical · score 70.0Price as of 17 Nov 2026Daily close, not a live quote
Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price30.64 USD at the 17 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 17 Nov 2026
- Our regime readMarkup, as of 16 Nov 2026
- Ethical screenPasses, score 70.0 out of 100
- Last reviewed17 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $31.00 to $45.00, base estimate $34.00 (screen dated 2026-11-17).
- Trend Markup
- Insiders insiders sold, $2,941,571, latest filing 2026-11-11
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Alamar Biosciences, Inc. holds its Markup at $30.64. Elevated stress, defensive posture warranted, held for 12 days.
| Phase | Markup |
| Quantitative state | Elevated stress, defensive posture warranted, held for 12 days |
| Price at the screen | $30.64 |
| Valuation | N/A trailing · -64.72 forward price to earnings |
| Values screen | PASS · score 70.0 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 29.63% | Below 33% | Interest-bearing debt is just 29.6% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 30.54% | Below 49% | Money owed to the company is 30.5% of assets, under the 49% limit. | Pass |
| Revenue purity | 2.91% | Below 5% | Only 2.9% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Alamar Biosciences, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 30%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ALMR's ethical verdict changes
Today ALMR passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 17 Nov 2026: it trades at roughly a 10% discount to our $34.00 fair value, 68.50% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 9.9% discount to the base estimate.
Third-party analyst targets. The average target sits +11% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $34.00, with a range of $31.00 to $45.00, dated to the 2026-11-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsEarly disease detection sounds promising but stays unproven
Imagine a blood test that spots disease proteins years before symptoms appear. Alamar Biosciences is racing to build that with its NULISA platform, selling instruments and consumables into a market hungry for better diagnostics. Revenue is doubling each year at 99 percent, the shares trade below our calculated fair value, and the business clears our ethical screen without issue.
Yet the numbers still give pause. Margins sit at minus 50 percent, the forward multiple is deeply negative, and no clear moat protects the technology from larger rivals. Five analysts call it a buy with a 32 dollar median target, but that optimism rests on forecasts that have yet to turn into sustained profits.
High growth in medical tools often masks how long it takes to reach scale and steady cash flow. We therefore pass. Analysis, not advice.
| Forward P/E | -64.7x |
| EPS, trailing | -1.13 |
| EPS, forward | -0.42 |
| Revenue growth | +68.5%growing very fast |
| Profit margin | -48.2%currently unprofitable |
| Debt to equity | 0.14minimal debt: a conservative balance sheet |
| Current ratio | 9.49comfortably covers its short-term bills |
| Short interest, float | 0.06% |
| 52-week range | 18.85 - 39.61 |
| Market cap | $1.9B |
| Employees | 222 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeALMR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 10.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 7.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. The street (5 analysts) rates it none, with a mean price target of $30. Insiders have been net sellers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Is GSK (LSE:GSK) A Bargain Following Its New Alamar Collaboration? Yahoo Finance · 5d ago
- Why Is GSK (LSE:GSK) Drawing Attention For New Cancer Data And Proteomics? Yahoo Finance · 9d ago
- Does Alamar Biosciences (ALMR) Sit Above Fair Value After The Selloff? Yahoo Finance · 13d ago
- Alamar Biosciences to Participate in Upcoming Investor Conferences Yahoo Finance · 13d ago
- Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript Yahoo Finance · 14d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-11 | Qiming Corporate Gp Vi, Ltd. | 10% | S - Sale | 100,117 | $2,941,571 |
| 2026-10-27 | Qiming Corporate Gp Vi, Ltd. | 10% | S - Sale | 185,731 | $5,968,888 |
| 2026-10-23 | Qiming Corporate Gp Vi, Ltd. | 10% | S - Sale | 280,458 | $8,569,760 |
| 2026-10-21 | Qiming Corporate Gp Vi, Ltd. | 10% | S - Sale | 342,626 | $10,253,095 |
| 2026-10-15 | Qiming Corporate Gp Vi, Ltd. | 10% | S - Sale | 173,673 | $4,816,121 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $23.88 | -10.5% | · | $895 | -10.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ALMR does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.